Ristova Ristova MABTHERA MABTHERA

Dose: 375 mg/m2
Single Dose: 380 (375)
Frequency: As recommended.
Route: IV-Inf
Instructions: Once weekly for 4 doses.

. It is of Natural origin. .

Rituximab is contraindicated in conditions like Breast feeding,Hypersensitivity to any component of product,Hypersensitivity to murine proteins.

The symptomatic adverse reactions produced by Rituximab are more or less tolerable and if they become severe, they can be treated symptomatically, these include Blood dyscrasias, Affectced liver function.

'Rituximab is primarily indicated in conditions like Advanced follicular lymphoma(chemo resistant), Non-hodgkin''s lymphoma, and can also be given in adjunctive therapy as an alternative drug of choice in Sedation with amnesia.'

Rituximab is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementCerivastatin SodiumCerivastatin sodium reduces effect of RituximabCisplatinCisplatin because serious kidney toxicity or kidney failure may occur. ClozapineThe use of clozapine with other potentially myelotoxic agents may increase the risk and severity of hematologic toxicity due to additive pharmacodynamic effects. Clozapine alone may cause agranulocytosis, and the risk may theoretically increase when coadministered with other myelotoxic therapy.MajorClozapine should not be used concomitantly with other agents having a well-known potential to cause agranulocytosis or otherwise suppress bone marrow function.DiphtheriaTetanus-Acellular Pertussis VaccineConcurrent use may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Ganciclovir (Na)Ganciclovir (Na) may increase the risk and severity of hematologic toxicity due to additive pharmacodynamic effects. ModerateLeflunomideThe use of leflunomide in combination with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant immunosuppressive therapy.MajorClose monitoring for the development of infection is recommended if leflunomide is used in patients who have recently received or are receiving other immunosuppressive or myelosuppressive agents.Measles VaccineThe administration of live, attenuated virus or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence.MajorThe administration of live, attenuated virus or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence.Mumps VaccineThe administration of live, attenuated virus or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence.MajorThe administration of live, attenuated virus or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence.Rubella VaccineThe administration of live, attenuated virus or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence.MajorThe administration of live, attenuated virus or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence.TorasemideAdditive antihypertensive effects may occur. Increased risk of hypotension. Consider withholding Torasemide for 12 hours prior to administration of Rituximab. These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Drug should not be given to Cardiac / Hypertensive Patients, and patients suffering from Liver Malfunction.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Inj Store . Do not Freeze. Protect from Sunlight and Heat.

Pregnancy. Rituximab should be used with caution in patients receiving cardiotoxic chemotherapy or with a history of cardiovascular disease because exacerbation of angina, arrhythmia, and heart failure have been reported. Transient hypotension occurs frequently during infusion and antihypertensives may need to be withheld for 12 hours before infusion.